Closing the doughnut hole: No easy answers

Health Affairs

Volumn 23, Issue SUPPL. 2, 2004, Pages

  Danzon, Patricia M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG CONTROL; DRUG COST; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; GOVERNMENT; REVIEW; UNITED STATES;

EID: 12944336670     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.W4.405     Document Type: Review

References (6)

1. G.F. Anderson et al., "Doughnut Holes and Price Controls," Health Affairs, 21 July 2004, content.healthaffairs.org/cgi/content/abstract/ hlthaff.w4.396.
2. P.M. Danzon and M. Furukawa, "Prices and Availability of Pharmaceuticals: Evidence from Nine Countries," Health Affairs, 29 October 2003, content.healthaffairs.org/cgi/content/abstract/hlthaff.w3.521 (12 July 2004).
3. Data from the International Monetary Fund (IMF), 2003. The differentials using purchasing power parities (PPPs) are 18 percent for Canada, 24 percent for France, and 25 percent for the United Kingdom (2001 data). PPP-based comparisons may provide a better measure of relative purchasing power, but since exchange rates are used for comparing drug prices, they should also be used for comparing incomes.
4. J.P. Newhouse, "How Much Should Medicare Pay for Drugs?" Health Affairs 23, no. 1 (2004): 89.
5. Danzon and Furukawa, "Prices and Availability."
6. See M.V. Pauly, "Medicare Drug Coverage and Moral Hazard," Health Affairs 23, no. 1 (2004): 113.